Roche's CT-388: A Game-Changer in the Obesity Drug Space? - AInvest

Retrieved on: 2025-09-22 22:18:55

Tags for this article:

Click the tags to see associated articles and topics

Roche's CT-388: A Game-Changer in the Obesity Drug Space? - AInvest. View article details on hiswai:

Excerpt

- Roche's CT-388, a dual GLP-1/GIP agonist, advances to phase 3 trials with 18.8% average weight loss, challenging Novo Nordisk and Eli Lilly's ...

Article found on: www.ainvest.com